To order this detailed 320+ page
report, please visit this link
Key Inclusions
§ A detailed assessment of the current market landscape,
providing information on drug developer(s), phase of development (marketed,
clinical and preclinical / discovery stage) of lead candidates, type of
molecule (small molecule and biologic), type of treatment (personalized and
off-the-shelf), type of therapy (monotherapy and combination therapy), type of
immunotherapy, target indication, line of treatment, and route of
administration of the drugs / therapies that are being developed for the
treatment of cancer.
§ Detailed profiles of developers of neoantigen targeted
therapies (shortlisted on the basis of the number of pipeline products),
featuring an overview of the company, its financial information (if available),
a detailed description of its product portfolio and recent collaborations. In
addition, each profile includes an informed future outlook.
§ A detailed publication analysis of close to 300
peer-reviewed, scientific articles published during the period 2015-2019 (till
February), highlighting the research focus within the industry. It also
highlights the key trends observed across the publications, including
information on target disease indications, affiliated cancer immunotherapies,
and analysis based on various relevant parameters, such as study type (review
article, research article and meta-analysis), year of publication, and most
popular journals (in terms of number of articles published in the given time
period) within this domain.
§ An in-depth analysis of the various patents that have been
filed / granted related to neoantigens till April 2019. It includes information
on key parameters, such as patent type, publication year, issuing authority,
assigned CPC symbol, emerging focus areas and leading industry / academic
players (in terms of size of intellectual property portfolio).
§ An analysis of the various partnerships pertaining to
neoantigen targeting therapies, which have been established till March 2019,
based on various parameters, such as the type of partnership, year of
partnership, target disease indications, type of immunotherapy and the most
active players.
§ An analysis of the investments made, including seed
financing, venture capital financing, debt financing, grants, capital raised
from IPOs and subsequent offerings, at various stages of development in
companies that are focused on developing neoantigen targeted therapies.
§ Informed estimates of the existing market size and the
future opportunity for neoantigen targeted therapies, over the next decade.
Based on multiple parameters, such as disease prevalence, anticipated adoption
of neoantigen targeted therapies and the likely selling price of such
therapeutic products, we have provided informed estimates on the evolution of
the market for the period 2019-2030.
The report also
features the likely distribution of the current and forecasted opportunity
across important market segments, mentioned below:
§
§
§
§
§
§
§
§
§
§
§
§
Press
Release: Variation 4 (Format 5)
§
§
§
§
§
§
§
§
§
§
§
§
The
report also features inputs from eminent industry stakeholders, according to
whom neoantigen targeted therapies are expected to be the next big step in
cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so
far, demonstrated significant therapeutic potential and promising clinical
outcomes. The report includes detailed transcripts of discussions held
with the following experts:
§ Gabriel
Nistor (Chief Science Officer, AIVITA Biomedical)
§ Ella
Sorani (Vice President Research and Development, BioLineRx)
§ Heinz Lubenau (Chief Operating Officer & Co-founder,
VAXIMM)
To
request sample pages, please visit this link
Key Questions Answered
§ What are the prevalent trends related to R&D activity
focused on neoantigen based therapies?
§ What are the clinical conditions for which neoantigen
targeted therapies are being developed?
§ What are the key challenges faced by neoantigen-based
therapy developed?
§
§
§
§
§
§ How is the current and future market opportunity likely to
be distributed across key market segments and geographies?
You
may also be interested in the following titles:
1. T-Cell Immunotherapies Market (4th
Edition), 2019-2030
2. Novel Immuno-Oncology Biomarker
Testing Market, 2019-2030
3. Companion Diagnostics Market (2nd
Edition), 2019-2030
Contact
Us:
Gaurav
Chaudhary
+1 (415) 800 3415